Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Lymphoma cell DNA cytometry in imprints of dissected lymph nodes was performed in 98 patients with low grade non-Hodgkin lymphomas and in 15 patients with reactive lymphadenopathy. The percentage of resting and proliferating cells was also calculated on the basis of computer analysis of DNA amount and cell image. It has been shown that, in contrast to the control group characterized by diploidic DNA amount, DNA aneuploidy was observed in 63.3% of lymphoma patients (DNA hyperdiploidy in 58.2% and DNA aneuploidio-polyploidy in 5.1% of the studied group). The proliferative activity of lymphoma cells was higher in patients with DNA aneuploidy than in DNA diploidic patients and in the control group.
Acta Haematol Pol 1993
PMID:[DNA--ploidy in non hodgkin's lymphomas of low malignancy]. 837 15

Porphobilinogen deaminase activity was studied in the erythrocytes of 73 women and 35 men with various malignant proliferative disorders of the lymphatic system and bone marrow, and, for comparison, in the erythrocytes of 34 women and 14 men with non malignant diseases of the haemopoietic system, and in those of 20 healthy women and 20 healthy men. The activity of the enzyme was determined by the Hsiao et al. method, using porphobilinogen as a substrate. Statistical analysis showed a significant decrease of porphobilinogen deaminase activity in the erythrocytes of men with Hodgkin's disease and women with plasmocytoma and with myeloblastic leukemia; an increased activity of the studied enzyme was found only in men with lymphocytic leukemia.
Patol Pol 1993
PMID:Porphobilinogen deaminase activity in malignant proliferative disorders of the lymphatic system and bone marrow. 848 77

In 69 patients (pts) with Hodgkin's disease (HD) in I-IIIA clinical stage results of abdominopelvic computed tomography (CT) were compared with pathological staging. Concordance (specificity) of CT scan with results of macroscopic evaluation of HD lesions in the abdomen during laparotomy with splenectomy was 83%. Accuracy CT results and microscopic findings was 80%. False positive results of CT were found in 11.6% of patients and false negative in 8.6%. Specificity and sensitivity of CT versus to pathological staging were 84% and 63% respectively. The results presented here confirm, that pathological staging after laparotomy with splenectomy in HD was some advantage in precise prediction of some patients to radiotherapy and planning of irradiated fields.
Acta Haematol Pol 1993
PMID:[Comparison of computed tomography results and pathological findings after laparotomy with splenectomy in Hodgkin's disease]. 848 34

61 patients with Hodgkin's disease, i.e., 40.9% of all HD pts hospitalized in the years 1970-1981 are more than 10 years survivors: 46 are alive and 15 died of underlying disease or its complications. The most important prognostic factor at diagnosis was clinical advancement and the form A or B of HD. Age and sex also influenced survival but to a lesser degree. Patients living in CCR were more likely to have MC histology than those with relapsing disease, who more often showed LD and LP type. Among 5 persons with second neoplasms four disclosed NS type of HD. No statistical differences in clinical prognostic factors were encountered between further alive and those who died after more than 10-yrs. Almost all patients were able to normally continue their familial and professional lives.
Acta Haematol Pol 1993
PMID:[Long-term (over 10-years) survival in Hodgkin's disease]. 848 35

Among 330 patients with Hodgkin's disease, in five development of fistula between the respiratory and alimentary tract was observed; tracheoesophageal in three and bronchoesophageal in two patients. Generalization of the disease was the cause of fistula in three patients; it appeared as a result of necrosis of the neoplastic infiltration during cytostatic treatment or radiotherapy. In the fourth patient the fistula was of iatrogenic origin (radiation induced damage), and in the fifth it was the result of secondary neoplasm (bronchial anaplastic cancer).
Acta Haematol Pol 1993
PMID:Tracheo- and bronchoesophageal fistulas in Hodgkin's disease. 848 40

A case of a healthy 23-year-old woman is reported with cytomegalovirus mononucleosis as a result of infection of cytomegalovirus probably primary. The patient presented with symptoms of generalized adenopathy, migratory arthralgias and arthritis, hepatosplenomegaly, long lasting rash as well as complications of pneumonia and myocarditis. Because on histopathological examination of lymph node the Hodgkin-Reed-Sternberg-like cells were found a misdiagnosis of Hodgkin's disease was initially made. After about 8 weeks period there was a complete recovery. The current problems related to cytomegalovirus infection are presented.
Pol Arch Med Wewn 1995 Jul
PMID:[Difficulties in diagnosis of cytomegalovirus mononucleosis syndrome]. 852 1

Fludarabine, an analogue of arabinosyl adenine, used since 1986 proved to be a new agent effective particularly in chronic lymphocytic leukaemia. About 35% of patients refractory to previous cytostatic treatment and about 75% of untreated patients obtained complete remissions. Nearly 90% of them revealed no minimal residual disease and no relapse during 2 years of observation. Worse response was found in patients with other low grade non-Hodgkin's lymphomas.
Acta Haematol Pol 1995
PMID:[Fludarabine in the treatment of chronic lymphocytic leukemia and other lymphoproliferative disorders]. 852 71

In 38 patients with acute leukemias or non-Hodgkin's lymphomas of high malignancy the blood-brain barrier (BBB) was prospectively analysed by means of QAlb value (QAlb = cerebrospinal fluid albumin/serum albumin). Cerebro-spinal fluid and serum were taken before each intrathecal methotrexate administration according to central nervous system (CNS) prophylaxis or treatment of CNS involvement by neoplasm. Patients were divided into two groups. Group I consisted of 5 individuals with clinical manifestations of CNS involvement by leukemia or lymphoma. Group II contained 33 patients without neurological symptoms. Besides, group II was subdivided into other two groups: group IIa-patients with BBB analysis before cytostatics application, and group IIb-patients in which BBB was analysed after the administration of at least one cycle of protocols, used in general chemotherapy, including intrathecal methotrexate injection. In group I BBB changes were observed in 10 out of 12 assessments (sensitivity 83.3%). In group II BBB impairment was revealed in 11 out of 52 assessments (specificity 78.8%). The differences in QAlb values between groups I and II were statistically significant (p = 0.0008), whereas there were no significant differences between QAlb values in groups IIa and IIb. Basing on their investigations, the authors conclude that neoplasm invading CNS should be considered as essential risk of BBB impairment, whereas intrathecal and general chemotherapy appear to be less important in BBB injury.
Acta Haematol Pol 1995
PMID:[Dysfunction of the blood-brain barrier in patients with acute leukemias or lymphomas of high grade malignancy]. 852 76

Authors present 38-years old woman with 11-years lasting complete remission of Hodgkin's disease who was recognized to have non-Hodgkin's lymphoma of the base of the tongue and also of stomach three months later. After polychemotherapy complete remission was achieved.
Acta Haematol Pol 1995
PMID:[Non-Hodgkin's lymphoma in a patient after many years of remission of Hodgkin's disease]. 852 78

Hodgkin's disease (HD) is a malignant disease originating from hematopoietic tissue which is characterized by the presence of Hodgkin and Reed-Sternberg cells. The vast majority of HD patients are cured with current standard therapy. Both megavoltage radiotherapy and combination chemotherapy are effective treatment modalities. Radiotherapy is curative for localized Hodgkin's disease, and it is now generally agreed that advanced Hodgkin's disease can be cured by combination chemotherapy. Data from uncontrolled trials suggest that in patients with advanced disease the addition of low-dose radiation to sites of previous disease involvement is associated with better long term and relapse free survival. Patients who relapse after initial treatment with chemotherapy are considered suitable candidates for systemic salvage programs. These programs may include treatment with the same drugs, the use of non-cross resistant chemotherapy programs or investigational programs such as high dose chemotherapy with autologous or allogenic bone marrow rescue. An appropriate management decision depends upon assessment of the disease and also on the impact of treatment side effects on the individual patients.
Acta Haematol Pol 1995
PMID:[Progress and controversy in treatment of Hodgkin's disease]. 857 35


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>